logo
OVHcloud Receives the 2025 Global Service Provider Award at the Nutanix .NEXT Event

OVHcloud Receives the 2025 Global Service Provider Award at the Nutanix .NEXT Event

Business Wire12-05-2025

RESTON, Va. & WASHINGTON--(BUSINESS WIRE)-- OVHcloud, a global full-service cloud provider, announced today during Nutanix 's .NEXT conference that it has been awarded the 2025 Global Service Provider Nutanix Partner Award.
Nutanix, a leader in hybrid multicloud computing, recognized OVHcloud for its all-in-one and scalable Nutanix® on OVHcloud hyper-converged infrastructure (HCI). OVHcloud helps companies deploy Nutanix Cloud Platform™ (NCP) software licenses on dedicated, Nutanix-qualified OVHcloud Hosted Private Cloud infrastructure.
'We are thrilled to recognize OVHcloud as our 2025 Global Service Provider of the Year,' said Dave Gwyn, Senior Vice President of Worldwide Channels at Nutanix. 'OVHcloud has consistently prioritized customer success with concrete contributions to the cloud ecosystem. As customers increasingly look to reduce IT complexity, simplify operations, and run applications and manage data anywhere they need it, we look forward to working further with OVHcloud across their markets.'
OVHcloud's global NCP-enabled infrastructure is designed for seamless hybrid multi-cloud integration, datacenter exit, disaster recovery and managed disaster recovery as a service (DRaaS), and more. Through OVHcloud, enterprises can use their full stack offering inclusive of Nutanix software or bring their own licenses to run on OVHcloud's bare metal servers. This allows businesses to optimize workload performance and data mobility across different clouds.
'We are delighted to be recognized by Nutanix as the 2025 Global Services Provider for the Nutanix Cloud Platform,' said Yaniv Fdida, Chief Product and Technology Officer at OVHcloud. 'This recognition is a testament to the industry-leading Nutanix customers and partners we serve. We look forward to continuing our partnership and further innovating on our solution enabled by the Nutanix Cloud Platform.'
'We are extremely honored to be recognized by Nutanix with the 2025 Global Service Provider Nutanix Partner Award,' said Jeffrey Gregor, General Manager of OVHcloud US. 'We're thankful to Nutanix for this acknowledgment of our multinational efforts, as well as for their continued support and partnership. We remain committed to work together to help our customers simplify and accelerate the delivery of cutting-edge infrastructure solutions where and when they are needed most.'
The award was presented at Nutanix's .NEXT conference, a three-day event for information technology services professionals. The event features keynotes, demonstrations, breakout sessions, and hands-on labs all designed to support the future of digital workloads.
About OVHcloud US
OVHcloud US is a global player and the leading European cloud provider operating over 450,000 servers within 43 data centers across 4 continents to reach 1.6 million customers in over 140 countries. Spearheading a trusted cloud and pioneering a sustainable cloud with great performance-price ratio, the Group has been leveraging for over 20 years an integrated model that enables OVHcloud to independently cover all the uses of its customers so they can seize the benefits of an environmentally conscious model with a frugal use of resources and a carbon footprint reaching the best ratios in the industry. OVHcloud now offers customers the latest-generation solutions combining performance, and predictable pricing, and complete data sovereignty to support their unfettered growth. us.ovhcloud.com.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting

Yahoo

timean hour ago

  • Yahoo

DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting

Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the 'Company'), held its Combined General Meeting (the 'General Meeting'). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company's shareholders approved all resolutions submitted by the Board of Directors. The resolutions and the voting results are posted on the Investors/Annual General Meetings section of the Company's website: About DBV TechnologiesDBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary technology platform, Viaskin™, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin's immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company's food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309). For more information, please visit and engage with us on X (formerly Twitter) and LinkedIn. Viaskin and EPIT are trademarks of DBV Technologies. Investor Contact Katie MatthewsDBV Media ContactAngela Marcucci DBV Attachment PDF VersionFehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split
AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

Yahoo

timean hour ago

  • Yahoo

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

OCALA, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (OTC Pink: AIMID) (NYSE American: AIM) ('AIM' or the 'Company') today announced a reverse stock split ('Reverse Stock Split') of its shares at a ratio of 1-for-100. The Reverse Stock Split will take effect at market open tomorrow, June 12, 2025. The Company's ticker symbol on the OTC Pink will be AIMID for 20 trading days, including the effective date. One of the primary goals of the Reverse Stock Split is to increase the per-share market price of the Company's common stock to enable the Company to regain compliance with the NYSE American's Listing Qualifications. At a Special Meeting of Stockholders held on April 30, 2025, the Company's stockholders approved a series of alternate amendments to the Company's Certificate of Incorporation to effect a reverse stock split of the Company's outstanding common stock at a ratio in the range of up to 1-for-100, with such ratio to be determined by the Company's Board of Directors. Stockholders will be given cash in lieu of any fractional shares on a post-split basis. Following the Reverse Stock Split, the new CUSIP number of the common stock will be 00901B303, with the par value per share of common stock remaining at $0.001. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit and connect with the Company on X, LinkedIn, and Facebook. Cautionary Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the 'PSLRA'). Words such as 'may,' 'will,' 'expect,' 'plan,' 'anticipate,' 'continue,' 'believe,' 'potential,' 'upcoming' and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy in any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@

Great Point Partners Acquires Majority Stake in Eutecma – Sustainable Temperature Controlled Pharmaceutical Packaging
Great Point Partners Acquires Majority Stake in Eutecma – Sustainable Temperature Controlled Pharmaceutical Packaging

Business Wire

timean hour ago

  • Business Wire

Great Point Partners Acquires Majority Stake in Eutecma – Sustainable Temperature Controlled Pharmaceutical Packaging

GREENWICH, Conn.--(BUSINESS WIRE)-- Great Point Partners ('GPP' or 'the Firm'), a Greenwich-based private investment firm focused exclusively on the health care industry, announced today the acquisition of a majority stake in Eutecma (or 'the Company'), a German-based developer of sustainable, modular, and reusable temperature controlled packaging solutions for pharmaceutical cold chain shipments. 'Nearly 17 years later we have the chance to make even greater strides, and we're thrilled to have GPP's support in this next phase of growth.' - Eutecma Co-Founder, Markus Baumgärtner Share Since its founding in 2008, Eutecma has been committed to producing passive cooling systems that make transport and logistics more sustainable and efficient. Eutecma is a leader in the pharmaceutical industry with its patented ICECATCH ® cooling systems being a top choice among pharmaceutical, medical, and laboratory diagnostics businesses. Eutecma's ' retecma ' has created a circular system for its packaging materials with an extensive network of Refreshment Centers. The process ensures materials remain in circulation for as long as possible while shrinking carbon dioxide (CO 2) emissions, and provides real-time CO 2 reduction data to clients. 'We have successfully created innovative and sustainable cold chain solutions that have proven themselves with well-known pharmaceutical customers,' said Eutecma Co-Founder, Florian Zeilfelder. 'Our work with GPP will advance that mission so we can strategically expand our reach, especially in the US and other geographies around the world.' 'Florian and I took a leap of faith when founding Eutecma because we knew we had an innovative idea for our industry,' said Eutecma Co-Founder, Markus Baumgärtner. 'Nearly 17 years later we have the chance to make even greater strides, and we're thrilled to have GPP's support in this next phase of growth.' With this partnership, Eutecma has also acquired Resolvision, Eutecma's proprietary re-use machine technology utilized at its Refreshment Centers. 'Eutecma impressed us with their innovative technology and approach to sustainability that is making a significant impact for pharmaceutical clients,' said Eddie Hjerpe, Senior Vice President at GPP. 'Their temperature performance, CO 2 reduction data, and differentiated engineering is exactly what the evolving cold-chain industry is looking for today.' 'Eutecma has the opportunity to further expand its global capabilities at a time when there's growing demand for reusability, cost-savings, and new cooling technologies within cold chain,' said Harrison Johnson, Vice President at GPP. 'This investment underscores our dedication to supporting exceptional high growth health care companies that assist in bringing lifesaving medicines to patients across the globe.' About Great Point Partners Great Point Partners ( founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 32 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new minority and majority private equity investments from GPP IV. Great Point manages approximately $1.5 Billion of capital in its private funds and public biotechnology equity strategy (BioMedical Value Fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, contract manufacturing and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. About Eutecma Founded in 2008 by co-founders Florian Zeilfelder and Markus Baumgärtner, Eutecma ( is a leading designer and manufacturer of sustainable, modular, and reusable temperature controlled packaging solutions for pharmaceutical clients. The Company is headquartered in Mannheim, Germany with Refreshment Centers in the EU and U.S. Eutecma's product portfolio is designed to be reused for multiple shipments, which enables clients to meet their sustainability initiatives while simultaneously yielding lower upfront and total cost of shipment compared to other TCP solutions. To pair with its reusable TCP solutions, Eutecma's 'retecma' program enables the evaluation of used packaging at their Refreshment Centers for evaluation and refurbishment before reusing or recycling the solutions for future shipments. This refurbishment process creates a circular economy whereby Eutecma products are reused until their end of life, at which point they are recycled creating a fully circular, sustainable economy.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store